Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients

European Journal of Clinical Pharmacology

Volumn 67, Issue 8, 2011, Pages 797-801

  Surendiran, A ^a   Pradhan, S C ^a   Agrawal, Aparna ^a   Subrahmanyam, D K S ^a   Rajan, S ^a   Anichavezhi, D ^a   Adithan, C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

CYP2C9; Diabetes mellitus; Glibenclamide; Pharmacogenetics

Indexed keywords

GLIBENCLAMIDE; METFORMIN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; DIABETES CONTROL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PRIORITY JOURNAL; REGULATOR GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ALLELES; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GENETIC ASSOCIATION STUDIES; GLYBURIDE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIA; MALE; METABOLIC DETOXICATION, PHASE I; METFORMIN; MIDDLE AGED; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 79960965105     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1013-8     Document Type: Article

References (20)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diab Care 27:1047-1053 (Pubitemid 38579764)
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17-30
3. Yin O, Tomlinson B, Chow S (2005) CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 78:370-377 (Pubitemid 41393672)
4. Adithan C, Gerard N, Vasu S, Balakrishnan R, Shashindran CH, Krishnamoorthy R (2003) Allele and genotype frequency of CYP2C9 in Tamilnadu population. Eur J Clin Pharmacol 59:707-709 (Pubitemid 37498209)
5. Kirchheiner J, Brockmöller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 77:1-16 (Pubitemid 40089477)
6. Wang B, Wang J, Huang SQ, Su HH, Zhou SF (2009) Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr Drug Metab 10:781-834
7. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72:326-332
8. Kirchheiner J, Brockmoller J, Meineke I, Bauer S, Rohde W, Meisel C et al (2002) Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71:286-296 (Pubitemid 34311458)
9. Asplund K, Wiholm BE, Lithner F (1983) Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24:412-417
10. Rajendran SD, Philip BK, Gopinath R, Suresh B (2007) RHPLC method for the estimation of glibenclamide in human serum. Indian J Pharm Sci 69:796-799 (Pubitemid 351380195)
11. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349 (Pubitemid 26288624)
12. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care 26[Suppl 1]:S5-S20
13. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M (2006) Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract 72:148-154
14. Kirchheiner J, Roots I, GoldammerM, Rosenkranz B, Brockmoller J (2005) Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 andCYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44:1209-1225 (Pubitemid 41832564)
15. Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359-371
16. Melander A, Donnelly R, Rydberg T (1998) Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 34:181-188
17. Beck-Nielsen H, Pedersen O, Lindskov HO (1979) Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol (Copenh) 90:451-462 (Pubitemid 9141959)
18. Hjollund E, Richelsen B, Beck-Nielsen H, Pedersen O (1983) The effect of glibenclamide on insulin receptors in normal man: comparative studies of insulin binding to monocytes and erythrocytes. J Clin Endocrinol Metab 57:1257-1262 (Pubitemid 14209429)
19. Lee CR, Pieper JA, Hinderliter AL, Blaisdell JA, Goldstein JA (2002) Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C9 heterozygotes. Clin Pharmacol Ther 72:562-571 (Pubitemid 36237728)
20. Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmoller J et al (2005) Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 60:103-106 (Pubitemid 40942788)